Christopher Kenney, MD

Chief Medical Officer

Christopher Kenney is the Chief Medical Officer at Cadent Therapeutics and brings extensive clinic research experience within neuroscience in both industry and academic roles. He most recently served as Senior Vice President of Medical Affairs at Acorda Therapeutics and launched INBRIJA™, a novel inhaled treatment for Parkinson’s disease. Prior to that position, Dr. Kenney worked 5 years as Vice President/Senior Vice president of clinical development, first at Biotie Therapies, and then Acorda, as the result of an acquisition. During that time, he led the development of a Phase II and a Phase III asset for Parkinson’s disease Dementia and motor fluctuations in Parkinson’s disease, respectively. Before joining Biotie, Dr. Kenney worked in clinical development at Novartis and Merck Serono. He has cared for patients and led clinical research teams as an attending neurologist while on faculty at the University of California San Diego (UCSD), Baylor College of Medicine and Boston University School of Medicine.

Dr. Kenney received his M.D. from the Boston University School of Medicine. He completed his neurology training at UCSD where he was Chief Resident and movement disorder fellowship training at the Baylor College of Medicine. Prior to his medical training, he spent 5 years conducting laboratory research including the development of oligonucleotides to target Interleukin-1β and the successful cloning of human MadCAM-1

Our Team

Christopher Kenney, MD

Chief Medical Officer

Christopher Kenney is the Chief Medical Officer at Cadent Therapeutics and brings extensive clinic research experience within neuroscience in both industry and academic roles. He most recently served as Senior Vice President of Medical Affairs at Acorda Therapeutics and launched INBRIJA™, a novel inhaled treatment for Parkinson’s disease. Prior to that position, Dr. Kenney worked 5 years as Vice President/Senior Vice president of clinical development, first at Biotie Therapies, and then Acorda, as the result of an acquisition. During that time, he led the development of a Phase II and a Phase III asset for Parkinson’s disease Dementia and motor fluctuations in Parkinson’s disease, respectively. Before joining Biotie, Dr. Kenney worked in clinical development at Novartis and Merck Serono. He has cared for patients and led clinical research teams as an attending neurologist while on faculty at the University of California San Diego (UCSD), Baylor College of Medicine and Boston University School of Medicine.

Dr. Kenney received his M.D. from the Boston University School of Medicine. He completed his neurology training at UCSD where he was Chief Resident and movement disorder fellowship training at the Baylor College of Medicine. Prior to his medical training, he spent 5 years conducting laboratory research including the development of oligonucleotides to target Interleukin-1β and the successful cloning of human MadCAM-1

Our Team

Christopher Kenney, MD

Chief Medical Officer

Christopher Kenney is the Chief Medical Officer at Cadent Therapeutics and brings extensive clinic research experience within neuroscience in both industry and academic roles. He most recently served as Senior Vice President of Medical Affairs at Acorda Therapeutics and launched INBRIJA™, a novel inhaled treatment for Parkinson’s disease. Prior to that position, Dr. Kenney worked 5 years as Vice President/Senior Vice president of clinical development, first at Biotie Therapies, and then Acorda, as the result of an acquisition. During that time, he led the development of a Phase II and a Phase III asset for Parkinson’s disease Dementia and motor fluctuations in Parkinson’s disease, respectively. Before joining Biotie, Dr. Kenney worked in clinical development at Novartis and Merck Serono. He has cared for patients and led clinical research teams as an attending neurologist while on faculty at the University of California San Diego (UCSD), Baylor College of Medicine and Boston University School of Medicine.

Dr. Kenney received his M.D. from the Boston University School of Medicine. He completed his neurology training at UCSD where he was Chief Resident and movement disorder fellowship training at the Baylor College of Medicine. Prior to his medical training, he spent 5 years conducting laboratory research including the development of oligonucleotides to target Interleukin-1β and the successful cloning of human MadCAM-1

Our Team